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F] FDG) is the most commonly used 
radiopharmaceutical in clinical positron emission tomography (PET) in oncology. 
Cancer cells create their own specific microenvironment to survive and grow. Specific 
tumor microenvironment contributes to cancer metabolic reprogramming. Therefore, 
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even with sufficient oxygen availability, cancer cells choose anaerobic glycolysis. 
Cancer cells compensate less energy efficient process by increasing the intensity of 
anaerobic glycolysis. Tumor cells have a high rate of metabolism and because of this, 
they take up more of the radioactive glucose (FDG). This makes the tumor cells 
appear more visible than other areas on the PET scan pictures.  
This paper presents nucleophilic synthesis of the [
18
F] FDG marker and basics 
of tumor development which can affect the [
18
F] FDG biochemical significance. 




Key words: synthesis [
18
F] FDG, glucose metabolism, [
18
F] FDG metabolism, 







The radiopharmaceutical consists of two basic parts, a carrier and an isotope. The 
carrier is a biologically active chemical compound involved in important biochemical 
processes, and the short-lived isotope is a positron emitter. Its task is to generate a 
signal that will be recorded by external detectors. The vehicle is labeled by placing a 
radioactive isotope molecule in its structure. 




F] FDG, the carrier is a 2-deoxy-D-






F] FDG is the most widely used radiopharmaceutical in the diagnosis of PET, 
showing various types of tumors characterized by increased glucose metabolism. The 
widespread use and commercialization of the [
18
F] FDG radiotracer contributed to the 
development of high-throughput synthesis methods, carried out using automated 
radiochemical modules [1,2]. 
The half-life of 
18
F isotope used for the production of [18F] Fluorodeoxyglucose 
is 110 minutes. It is long enough from the point of view of proper marker preparation 
and performance of the test procedure. The advantageous feature of the 
18
F isotope is 
the access to efficient cyclotron production that gives the possibility of obtaining the 
isotope in large quantities. In addition, 
18
F is characterized by high chemical reactivity 
and in chemical reactions it can be both a donor (nucleophile) and an electron 
acceptor (electrophile) [3]. 
 
 
Purpose of work 
The aim of this study is to present nucleophilic synthesis of the [
18
F]FDG 
marker and basics of tumor development which can affect the [
18
F]FDG biochemical 
significance. The reference was made to clinical images obtained in PET technology 
using the [
18






Description of knowledge 
Physical aspects of imaging techniques using properties of radiopharmaceuticals. 
Positron emission tomography is a emission method using positron emission 
tomography using [
18
F] FDG (PET). In contrast to the absorption methods, in the PET 
method, the image is generated on the basis of information sent from the object, 
which requires placing the source of this information in the tested object. The carrier 
of information in the PET technique is the quantum of gamma radiation, while the 
source of emitted radiation is the radiopharmaceutical collected in the body. 
PET technology is based on the use of isotopes being positronium emitters. The 
proton p in the nucleus of the isotope degrades 
+
 ( Energyenp e 
  ), in the 
radiopharmaceutical molecule, as a result of which neutron n is formed in the nucleus 
and electron neutrinos e and positronium e 
+
 emitting electron surplus are emitted 
from the nucleus. Positronium collisions with electrons is the center, staying a little 
way up to the loss of most of their energy. In the next step, he annihilates with the 
electron turning his mass into energy emitted in the form of two gamma quanta, 511 
keV each, in opposite directions. Annihilation is the basis on which PET technology 













Fig. 1. The scheme of positronium decay and annihilation 
 
 
If two scintillation detectors from the detector ring in a PET scanner, register a 
pulse in the same time window, so-called the coincidence window, we can assume 
that the line of annihilation has taken place between the two detectors and the 
radiopharmaceutical molecule must be there. This line is called the LOR (line of 
response) event line. The intersection of these roads indicates a greater concentration 
of the marker and is the basis for the reconstruction of images in PET diagnostics. The 
electronic coincidence allows direct determination of the direction from which 
information comes, so there is no need for additional collimators. Due to this, the 
sensitivity of the PET scanner is better than in the gamma cameras. In the case of 
pathological changes, the marker accumulates in a given process or place in the body, 
which gives the possibility of imaging at the tissue level. In that manner, PET 
technology allows to recognize pathological changes in their initial stages, the fastest 
among diagnostic imaging methods. This happens because biochemical changes are 
ahead of structural changes. However, the limited spatial resolution of PET images 
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reduces the amount of anatomical information. For this reason, at present, PET 
technology is most often fused with another medical imaging method that gives more 
structural information [4]. 
Other CT imaging methods include CT and MR. CT (computed tomography) is a 
diagnostic method using X-rays to obtain anatomical images containing information 
about the structure of organs and tissues. The fusion of PET and CT methods allows 
for more precise localization of the disease focus in the patient's body [5, 6]. 
Currently, among modern diagnostic solutions, fusion of PET and MR (magnetic 
resonance) methods is now available for patients. MR uses the properties of protons 
from the nuclei of hydrogen atoms in our body in the form of water molecules. Dipole 
water molecules containing hydrogen protons in their composition, in a strong 
magnetic field, magnetize, but after removing the field they return to the "balance" by 
sending radio waves that are registered by the detectors and based on them determines 
the density of the tested object as the basis for image reconstruction. One of the 
purposes of combining these two techniques is to obtain structural information of the 
object being imaged, similar to the case of PET / CT fusion. The advantage of PET / 
MR is, among others, on better imaging performance of soft tissues without additional 




F] fluorodeoxyglucose using nucleophilic fluorination 
Cyclotron production of radioactive 
18
F isotope 
This multistage process begins with the production of negatively charged 
hydrogen ions H-emitted from the ion source in the cyclotron. The ion source is 
supplied with hydrogen gas, which undergoes ionization due to the high potential 
between the cathode and the anode. Ionized hydrogen forms a plasma from which 
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negative ions are emitted into the accelerating region. These ions are introduced 
between the cyclotron electrodes of the so-called duant. Initially, the electric potential 
of the duant is positive in order to attract a negatively charged hydrogen ion, when the 
ion reaches the edge of the duant, the voltage potential changes to negative. The 
electric field is responsible for accelerating the ion beam, thus increasing their energy. 
The applied magnetic field curves the trajectory of charged particles directing them on 
a spiral trajectory in a cyclotron. Acceleration must take place in the vacuum chamber 
so that the particle does not lose energy during collisions, too low a vacuum could be 
a source of additional radionuclides. Ions H-obtained energy 11 MeV (energy of 
ejection), are directed to carbon film, which deprives hydrogen anions of two 
electrons. Depending on the model of the cyclotron, an inverting force with an 
inverted direction acts on the electrically modified H + particles, directing the ions to 
the cyclotron discs. The discs are made of chemically inert metals, i.e. titanium, 
niobium, tantalum. The disc substance is water enriched with oxygen isotope [18O] 








F [8,9,10].  
 
Uptake, purification and release of radioactive 18F isotope  
The 
18
F ion produced is in an aqueous solution. It is associated with a positively 
charged particle, a metal cation from the cyclotron target. In addition to the metal 
cation, water also lowers fluoride ion activity by forming hydrogen bonds with it. In 
the further stages of the synthesis, remove water together with metal cations from the 
reaction environment. 
In order to separate 
18
F- ion impurities to lower its activity fluoride solution and 
water is passed through an ion exchange column. The most commonly used column is 
QMA Sep - Pak light, which is filled with an organic polymer connected to 
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hydrocarbon chains containing at their ends - NR 3 + groups derived from quaternary 
ammonium salts. This group gives the ends of the hydrocarbon chain a positive 
charge. The counterion counterbalancing the positive charge of the end of the 
hydrocarbon chain are carbonate anions CO3
2-
 [11]. 
Anion exchange takes place on the column, fluoride is retained on the column's 
deposits, and water along with metal ions and CO3
2
 groups flows to the reclaimed 
water vessel [12]. 
The next step is to recover the fluoride anion from the QMA Sep - Pak light 
column by elution using the water - acetonitrile solution of Kryptofix (Kryptand 222) 
and K2CO3. Cryptands are organic compounds obtained synthetically, capable of 
forming complexes due to the structural matching of the metal cation to the cavity of 
the macrocycle system. In addition, they have the ability to transfer ions from the 
aqueous phase to the organic so-called the catalysis of interfacial transfer, desired in 
this type of reaction [13,14].  
Kryptofix binds in its structure - the recess, the K + cation derived from potassium 
carbonate. The potassium cation becomes a counterion to which for 
18
F- it has a 
higher affinity than to the positive ends of the hydrocarbon chain and is thus released 
from the QMA Sep-Pak light column and goes into the reaction vessel. In the 
presence of the Kryptofix structure, the K-
18
F bond weakens, and the fluoride anion 
becomes more aggressive and chemically reactive. In addition, the used cryptand 
transports the F-anion in the form of the K-18F complex from water to the aprotic 
solvent, which is acetonitrile [15,16,17]. 
During the elution, water residues also get into the reaction vessel, which must be 
removed. The acetonitrile present in the reaction vessel forms an azeotropic mixture 
with water. Evaporation of acetonitrile under a nitrogen atmosphere occurs at the 
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same time as evaporation of the rest of the water. In automatic synthesizers this 
process is repeated several times [12,15,16,17]. 
 
Nucleophilic substituent with radioactive fluorine to the precursor 
The purified, dried and high-activity fluoride anion is ready for nucleophilic 
substitution. The most frequently used precursor in the production of [
18
 F] FDG is 
1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-β-D-mannopyranose commonly 
known as mannose triflate. The precursor used possesses a trifluoromethanesulfonate 
leaving group at the 2-position (triflate), in position 1,3,4,6 protecting groups - acetyl. 
During the nucleophilic substitution reaction, the trifluorous group is replaced by the 
18
F fluorine isotope and the inversion of the spatial system of the C2 sugar 
substituents is made according to the mechanism of the 2D Snofotylic Snap 
(Sn2)nucleophilic substitution. The marking temperature should be 90 - 100 ° C, and 
the process should last a maximum of 5 minutes. Only after the fluoridation is 
completed, the aprotic solvent evaporates, supported by neutral gas [11,18]. 
 
Hydrolysis of the intermediate product 
 The final stage of the synthesis is the removal of protecting groups from the 
tetraacetyl - [
18
F] FDG sediment. The reaction takes place with hydrochloric acid 
at elevated temperature. Hydrolysis can also be carried out with a strong sodium base, 
the use of which does not require heating the solution, and this process takes place 
faster [19]. 
Purification of the final product 
 The purification of the crude end product is carried out by passing the final 
product mixture through a series of columns. The cation exchange column removes 
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the K + / K222 complexes, the ion delaying column neutralizes the acid, the column 
with neutral alumina removes unreacted 18F anions, the C18 column removes tetra-
acetyl [
18
F] FDG (Fig. 2) [20].  
 
 








Metabolism of glucose and [18F] FDG in cancerous cells 
Cancerous cells are characterized by unlimited replication potential, 
production of their own growth factors, resistance to apoptosis, ability to create 
their own blood vessel network, inducing inflammation, ignoring signals 
inhibiting proliferation and different cellular metabolism [21].  
Cancerous cells, to survive and grow, create their own specific 
microenvironment. One of the most important elements of creating such 
conditions is the ability of the tumor to create its own blood vessel network - 
angiogenesis. This network participates in supplying cells with nutrients, 
growth factors, adequate amount of oxygen and removing unnecessary 
metabolic substances. In physiological as well as tumor angiogenesis, vascular 
endothelial growth factor (VEGF) plays a major role. The nascent tumor 
network is significantly different from normal vessels. These are immature 
vessels with a disordered structure and variable blood flow resulting in cyclical, 
variable hypoxia. Lack of oxygen activates proangiogenic factors (including 
VEGF) inducing the formation of consecutive abnormally developed vessels. 
In this environment, the cancer metabolism is reprogrammed [22,23]. 
Activation of HIF1α hypoxia-inducible transcription factor (hypoxia inducible 
factor 1α) leads to inhibition of mitochondrial respiration and shifting glucose 
metabolism towards glycolysis. At the biochemical level, this occurs as a result 
of the inactivation of pyruvate dehydrogenase by the pyruvate dehydrogenase 
kinase and leads to a reduction of the conversion of pyruvate to acetyl-CoA. In 
addition, HIF1α is responsible for changes in the expression of many genes, 
493 
including overexpression of the glucose transporter 1 - GLUT 1 (glucose 
transporter 1) and enzymes involved in the glycolysis process. All these factors 
affect the increase in glucose metabolism [24]. 
Correct cells in the glycolysis process, under conditions of sufficient access 
to oxygen, metabolize glucose to pyruvate. Then acetyl - CoA formed from the 
pyruvate oxidation enters the Krebs cycle in which it undergoes oxidation to 
CO2 and H2O. As a result, one mole of glucose provides 30 (or 32) moles of 
ATP. Under conditions of limited access to oxygen, pyruvate is converted to 
lactic acid, of which only 2 moles of ATP are formed [25, 26]. Tumor-altered 
cells, even with sufficient oxygen availability, opt for anaerobic glycolysis, 
although it provides small amounts of ATP. This is because in the glycolysis 
process intermediate products are created, needed, among others for the 
synthesis of nucleic acids, proteins and lipids. Cancerous cells compensate for 
the choice of a less efficient process by increasing the intensity of anaerobic 
glycolysis 124 times. Increasing the intensity of this process increases the 
formation of intermediate products, sustains the supply of energy and nutrients 
at an appropriate level [21,24,27]. 
The described tumor feature was used in the diagnosis of tumor focuses 
using the positron emission tomography method using [
18
F] FDG. This 
compound is transported and metabolized by the same mechanisms as glucose, 
but there are some differences on the pathway. [
18
F] FDG is phosphorylated by 
hexokinase to 2- [
18
F] Fluoro-2-deoxy-glucose-6-phosphate and in this form it 




phosphate is not further transformed by phosphoglucose isomerase, due to the 
lack of adaptation of the enzyme to the molecule of this compound. After the 
18
F radioactive decomposition embedded in the [
18
F] FDG molecule, the 
oxygen formed with 
18
F combines with the hydrogen molecule to form a group 
[18O] -OH at the C2 carbon of glucose. The resulting glucose-6-phosphate is 
then converted by phosphoglucose isomerase and can undergo further 





Fig. 3. The mechanism of accumulation [
18






Tests performed using the described tag 
 
The purified preparation is a sterile colorless liquid which, after dilution with 
physiological saline, is administered intravenously to the patient for diagnostic 
purposes. The dose should be in the range of 400 - 700 MBq, in a maximum volume 
of 5 ml. The preferred techniques for assessing glucose analogue metabolism are PET 
/ CT and PET / MRI. In November 2009, the Committee of the European Society of 
Nuclear Medicine developed guidelines for the use of PET / CT imaging using [
18
F] 
FDG in the diagnosis of neoplastic diseases [29]. 
 Examination of [
18
F] FDG PET / CT has a higher sensitivity than CT scan in the 
diagnosis of a single nodule lung, staging of lung cancer, staging, control treatment 
and control the treatment of Hodgkin's lymphoma and lymphomas, non-Hodgkin's 
lymphoma, staging and diagnosis of recurrence in colorectal cancer, assessment of the 
severity, treatment control and diagnosis of recurrence of esophageal cancer, 
assessment of the severity of melanoma, especially in patients with suspected 
metastases to regional lymph nodes and metastases to distant organs [29]. 
Medical significance 
 However, the study using the described analog has some limitations. Too high 
glucose concentration in the blood of the patient may result in a reduction in [
18
F] 
FDG uptake at lesion sites, via competitive mechanisms. For this reason, patients are 
required to remain fasting before PET / CT studies using [
18
F] FDG. Difficulties arise 
in the diagnosis of patients with diagnosed diabetes. Specific rules for the preparation 
of patients included in the guidelines EANM- include, inter alia, maintaining an 
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appropriate interval from the last administered dose of insulin and oral hypoglycemic 
agents withdrawal. 
Figure 4 shows a scan from a PET / CT study using [
18
F] FDG in a patient who 
received metformin on the day of the study - high activity in the gut. Unfortunately, 
this mark does not work specifically on cancerous processes. Competitive 










Fig. 4. PET / CT examination using [
18
F] FDG after taking metformin - high activity 
in the gut. 
 
 
Figure 5 shows stimulation in the throat - probably resulting from the ongoing 
inflammatory process. A significant influence on FDG metabolism has also previous 
surgery or radiotherapy. However, the clinical situation of the patient does not always 
allow to maintain an adequate distance between the performed procedures and the 








Figure 6 shows metabolic stimulation within the uterus resulting from one 
month before the examination of the cervical conization. 
 
 
Fig. 6. Uterine PET examination using [
18
F] FDG  
 
 
When assessing the PET / CT examination, one should remember first of all 
about the physiological accumulation of radiopharmaceutical in the heart or liver, as 

















Described in this article [18F] FDG due to its versatility 
and the possibility of obtaining it in large quantities is the most commonly used 
radiopharmaceutical in the diagnosis of PET. [
18
F] FDG, however, possesses some 
drawbacks such as its non-specific uptake. In many cases highly differentiated 
tumours are difficult to distinguish from inflammation or infection using this 
radiopharmaceutical. In addition, [
18
F] FDG has a limited application in imaging 
tumors in the brain, muscles and bladder. The solution is to use tags specific to a 
given type of cancer. Currently, Positron Emission Tomography can choose from a 
large number of radiotracers: [
11
C] OCTAN - prostate cancer, [
18
F] DOPA - diagnosis 
of Parkinson's disease and neuroendocrine tumors, [
18
F] FET - brain tumors, [
18
F] 
FES - estrogen receptors in breast tumors and many others [30]. This should not be a 
reason to rest on your laurels. The future of Positron Emission Tomography will 
depend on research into new radiopharmaceuticals. Search should not be limited only 
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to the discovery of new molecules and attempts to attach a radioactive isotope to 
them. Researchers should also consider developing new synthesis methods to 
accelerate them, improve synthesis modules and isotope production equipment. 
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